Esco Lifesciences

The story begins in 1978 in Singapore, not with high-tech bioreactors, but with a focus on pioneering cleanroom technology for the local electronics industry. Founded by Lim Lay Yew, the company established itself by providing clean air solutions, building a foundation in controlled environments. This initial focus set the stage for a significant pivot into the life sciences. The transition saw Esco leverage its expertise to manufacture laboratory equipment, such as biological safety cabinets. This move proved successful, and under the leadership of the founding family, including current CEO XQ Lin, the company expanded its portfolio and global reach. Esco now operates distinct divisions for scientific equipment, IVF and medical devices, and pharmaceutical tools, serving clients in over 100 countries. A pivotal moment arrived in May 2021 when Esco Lifesciences secured a major $200 million Series A funding round. Led by prominent global investors like Vivo Capital and Novo Holdings, this capital injection was earmarked for strategic acquisitions and expansion, particularly in China and the U.S. Following this, the company pursued a Hong Kong IPO in late 2022, though the listing was ultimately cancelled. Today, Esco continues to grow through strategic acquisitions, such as its 2023 purchase of CESCO Bioengineering, reinforcing its position as a key player bridging life sciences technology between Asia, Europe, and North America.